Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview (Q41674262)

6 October 2017

1 reference

title

Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview (English)

1 reference

6 October 2017

2

1 reference

6 October 2017

Doncker PD

1

1 reference

6 October 2017

Marynissen G

series ordinal

3

1 reference

6 October 2017

Stoffels P

series ordinal

4

1 reference

6 October 2017

Heremans A

series ordinal

5

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

Journal of the American Academy of Dermatology

6 October 2017

published in

1 reference

6 October 2017

volume

37

1 reference

6 October 2017

issue

6

1 reference

6 October 2017

page(s)

969-974

1 reference

In vitro studies with R 51,211 (itraconazole)

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Pharmacokinetic profile of orally administered itraconazole in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Meta-analysis for combining Bayesian probabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Antifungal agents: an overview. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Adherence of dermatophyte microconidia and arthroconidia to human keratinocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in the treatment of superficial mycoses--a double-blind study vs. placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in the management of chronic dermatophytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Tinea pedis (mocassin-type) treated with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole Compared with Griseofulvin in the Treatment of Tinea corporis/cruris and Tinea pedis/manus: An Interpretation of the Clinical Results of all Completed Double-Blind Studies with Respect to the Pharmacokinetic Profile

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in the treatment of tinea corporis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in the treatment of tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in pityriasis versicolor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Treatment of dermatophytoses and pityriasis versicolor with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Treatment of pityriasis versicolor with itraconazole: a double-blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia furfur produced during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole for the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

An evaluation of itraconazole in the management of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 36 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970074-4

7 January 2021

10.1016/S0190-9622(97)70074-4

Identifiers

DOI

1 reference

6 October 2017

1 reference